These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
407 related articles for article (PubMed ID: 21904379)
1. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Lengfelder E; Hofmann WK; Nowak D Leukemia; 2012 Mar; 26(3):433-42. PubMed ID: 21904379 [TBL] [Abstract][Full Text] [Related]
2. Acute promyelocytic leukemia: a paradigm for differentiation therapy. Grimwade D; Mistry AR; Solomon E; Guidez F Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254 [TBL] [Abstract][Full Text] [Related]
3. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642 [TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia. Zhang Y; Zhang Z; Li J; Li L; Han X; Han L; Hu L; Wang S; Zhao Y; Li X; Zhang Y; Fan S; Lv C; Li Y; Su Y; Zhao H; Zhang X; Zhou J Cancer; 2013 Jan; 119(1):115-25. PubMed ID: 22930197 [TBL] [Abstract][Full Text] [Related]
5. How to manage acute promyelocytic leukemia. Mi JQ; Li JM; Shen ZX; Chen SJ; Chen Z Leukemia; 2012 Aug; 26(8):1743-51. PubMed ID: 22422168 [TBL] [Abstract][Full Text] [Related]
6. What is the role of arsenic in newly diagnosed APL? Tallman MS Best Pract Res Clin Haematol; 2008 Dec; 21(4):659-66. PubMed ID: 19041605 [TBL] [Abstract][Full Text] [Related]
7. Acute promyelocytic leukemia: recent advances in diagnosis and management. Lo-Coco F; Ammatuna E; Montesinos P; Sanz MA Semin Oncol; 2008 Aug; 35(4):401-9. PubMed ID: 18692690 [TBL] [Abstract][Full Text] [Related]
8. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309 [TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis. Wang H; Chen XY; Wang BS; Rong ZX; Qi H; Chen HZ Leuk Res; 2011 Sep; 35(9):1170-7. PubMed ID: 21774985 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. Ghavamzadeh A; Alimoghaddam K; Rostami S; Ghaffari SH; Jahani M; Iravani M; Mousavi SA; Bahar B; Jalili M J Clin Oncol; 2011 Jul; 29(20):2753-7. PubMed ID: 21646615 [TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide: an ancient drug revived. Zhou J Chin Med J (Engl); 2012 Oct; 125(19):3556-60. PubMed ID: 23044323 [TBL] [Abstract][Full Text] [Related]
12. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis]. Xu SN; Chen JP; Liu JP; Xia Y Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733 [TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia. Leu L; Mohassel L Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784 [TBL] [Abstract][Full Text] [Related]
14. Long-term remission after first-line single-agent treatment with arsenic trioxide of relapsed acute promyelocytic leukemia in an 8-year-old boy. Ebinger M; Schwarze CP; Feuchtinger T; Scheel-Walter HG; Lang P; Hildenbrand S; Gessler P; Handgretinger R Pediatr Hematol Oncol; 2011 May; 28(4):334-7. PubMed ID: 21345080 [TBL] [Abstract][Full Text] [Related]
15. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia. Quezada G; Kopp L; Estey E; Wells RJ Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388 [TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease. Breccia M; Lo-Coco F Expert Opin Pharmacother; 2012 May; 13(7):1031-43. PubMed ID: 22468778 [TBL] [Abstract][Full Text] [Related]
17. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Zhou J; Zhang Y; Li J; Li X; Hou J; Zhao Y; Liu X; Han X; Hu L; Wang S; Zhao Y; Zhang Y; Fan S; Lv C; Li L; Zhu L Blood; 2010 Mar; 115(9):1697-702. PubMed ID: 20029047 [TBL] [Abstract][Full Text] [Related]
18. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. Mathews V; George B; Chendamarai E; Lakshmi KM; Desire S; Balasubramanian P; Viswabandya A; Thirugnanam R; Abraham A; Shaji RV; Srivastava A; Chandy M J Clin Oncol; 2010 Aug; 28(24):3866-71. PubMed ID: 20644086 [TBL] [Abstract][Full Text] [Related]
19. Differentiation syndrome in patients with acute promyelocytic leukemia. Rogers JE; Yang D J Oncol Pharm Pract; 2012 Mar; 18(1):109-14. PubMed ID: 21364078 [TBL] [Abstract][Full Text] [Related]
20. Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia cell line. Noh EK; Kim H; Park MJ; Baek JH; Park JH; Cha SJ; Won JH; Min YJ Leuk Res; 2010 Nov; 34(11):1501-5. PubMed ID: 20226526 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]